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Abstract: Analogously to the natural selective forces in ecosystems, therapies impose selective
pressure on cancer cells within tumors. Some tumor cells can adapt to this stress and are able
to form resistant subpopulations, parallel with enrichment of cancer stem cell properties in the
residual tumor masses. However, these therapy-resistant cells are unlikely to be sufficient for the
fast tumor repopulation and regrowth by themselves. The dynamic and coordinated plasticity of
residual tumor cells is essential both for the conversion of their regulatory network and for the
stromal microenvironment to produce cancer supporting signals. In this nursing tissue “niche”,
cancer-associated fibroblasts are known to play crucial roles in developing therapy resistance and
survival of residual stem-like cells. As paracrine messengers, extracellular vesicles carrying a wide
range of signaling molecules with oncogenic potential, can support the escape of some tumor cells
from their deadly fate. Here, we briefly overview how extracellular vesicle signaling between
fibroblasts and cancer cells including cancer progenitor/stem cells may contribute to the progression,
therapy resistance and recurrence of malignant tumors.
Keywords: extracellular vesicles; cancer stem cell; cancer cell-fibroblast interaction; therapy resistance
1. Introduction
Darwin’s natural selection theory in ecosystems shares many similarities with the evolution of
tumors considering that cancer cells can adapt to their ever-changing microenvironment affected also by
therapeutic interventions [1,2]. The genetic and epigenetic changes cooperatively produce intratumoral
heterogeneity, which may promote the development of competitive cancer cell phenotypes [3].
Of the selection advantages provided by intratumoral heterogeneity, increased therapeutic resistance
represents one of the greatest challenges in the clinical management of cancer patients [4]. Even after a
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seemingly successful therapy, a small population of tumor cells may survive as a minimal residual
disease, which frequently remains hidden even to sensitive radiological imaging or histological
examination [5]. Cells of minimal residual disease may develop through positive selection of newly
mutated, resistant clones (clonal evolution hypothesis). Alternatively, they may originate from resistant
cancer stem cells (CSCs), which lie at to the top of the tumor hierarchy (cancer stem cell hypothesis) [6–8].
These two models are not mutually exclusive and both may contribute to intratumoral heterogeneity [9].
The similarities in developmental stages, receptor expression patterns and self-renewal capacities
of normal stem cells and CSCs raise the possibility that malignantly transformed normal stem cells
may be a source of CSCs during tumor initiation [10,11]. In tumors that follow the CSC model,
cancer cells can exist in different states of differentiation with a CSC population of relatively high
replicative potential (producing highly proliferating transit-amplifying cells), which can contribute
to intratumoral heterogeneity in the parent tumor [9,12–14]. In solid tumors, CSCs are identified by
specific markers or marker combinations (e.g., CD44 and CD24 in breast cancer; CD133, CD166 and
aldehyde dehydrogenase in colorectal cancer; CD133, CD44, aldehyde dehydrogenase and epithelial
cell adhesion molecule in pancreatic cancer) [15]. Parallel testing of marker expression and CSC function
(e.g., sphere formation ability) can be useful with some limitations (e.g., not all tumor-initiating cells
show CSC markers, and some CSC marker positive cells may not behave as CSCs) [16]. The genotypic
and phenotypic heterogeneity in the CSC population may serve as a critical reservoir for evolutionary
tumor progression that enables adaptation to therapies [9,17,18]. In general, CSCs may be inherently
resistant to apoptosis induction by cytotoxic agents and to radiation therapy (RT) as compared to the
less undifferentiated bulk cancer cells [19]. As a consequence, even when the tumor mass is reduced,
CSCs enriched in mutations, may accumulate within the remainder of the tumor [20,21]. These results
strongly suggest that CSCs are responsible for the therapy-resistant populations of residual disease.
For the survival of minimal residual disease, it may be critical that some cancer cell fates do not fit
into the unidirectional hierarchical CSC model, and show dedifferentiation towards the progenitor or
stem cell state (“cancer cell plasticity”) [13]. A high degree of cancer cell plasticity can be found both
in epithelial-to-mesenchymal transition (EMT) and in proneural-to-mesenchymal transition where
mesenchymal cells may acquire CSC-like characteristics [22,23].
Cancer cells can interfere with the physiological organization and the initial tumor-suppressing
effect of the adjacent microenvironment [24]. As a response, the aberrant stroma composed of
varying proportions of reactive cell types may produce extracellular matrix, enzymes and soluble
growth factors to generate a functionally complex cancer supporting milieu, as described in Paget’s
‘seed-and-soil’ hypothesis [25]. During tumor evolution, malignant cells can also force plasticity
in their microenvironment through instructive paracrine signaling. Locally acting regulators may
induce stromal heterogeneity even around the same lesion due to the varying sensitivity of target cells.
This could be the result of heterogeneous receptor expression/sensitivity, inflammatory or metabolic
signals, acidic pH shift, as well as oxygen and nutrient supply [4,26–29]. Of these factors, hypoxia
seems to be of particular importance in maintaining stem cell properties (including undifferentiated
and slowly-dividing states and maintenance of the stem cell niche) [30–32]. Cancer cells respond to
these regional differences. Therefore, stromal heterogeneity may deliver locally variable selection forces
and promote intratumoral heterogeneity [20]. Moreover, radiation therapy (RT) and chemotherapy
can also impose additional pressure on the tumor microenvironment resulting in phenotypically and
metabolically modified stromal cell subpopulations [33–37]. Anti-cancer therapies can induce alarm
signals in tumor-stroma interactions, which can select out cancer cells of CSC phenotypes, and activate
cells in the adjacent stroma. Results of in vitro and in vivo studies (see examples below) suggest that a
molecular symbiosis may evolve between cancer cells and stroma with potentially unfavorable clinical
behavior. Among the non-immune cell types of the tumor stroma, carcinoma-associated fibroblasts
(CAFs) are the most abundant ones in almost all solid tumors [38]. CAFs are heterogeneous and
they consist of diverse subpopulations of cells found at different stages of their maturation [34,39,40].
Contrary to the tumor-suppressing role of fibroblasts and myofibroblasts in normal tissues, CAFs
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can provide functional and structural support to malignant cells [41–43]. Figure 1 summarizes the
presumed changes in (i) cell number, (ii) intratumoral heterogeneity [44], (iii) presence of CSCs (in breast
and colorectal cancer models [45–47]), and (iv) in CAF population (in breast cancer models [34,48] and
hypothetically, based on a gastric cancer model [49]) during and after the therapy.
Cancer cells and the adjacent stroma may communicate through diverse pathways, such as
soluble regulators, tunneling nanotubes, tumor microtubules and/or connexin channel-mediated direct
intercellular connections [50–53]. One of the most prominent discoveries of recent years has been
the recognition that an extracellular vesicle (EV)-based information exchange takes place between
cells in nature. A continuous reciprocal EV-mediated communication also occurs between cancer
cells and adjacent stroma cells. EVs are membrane-enclosed vesicles, which carry unique molecular
signatures of various regulatory ligands, coding and non-coding nucleic acids, proteins, energy-rich
metabolites as well as whole organelles [54]. Several hallmarks of cancer, including altered proliferative
properties, growth suppression, cell death, energy metabolism, tumor microenvironment and acquired
genomic instability are known to be affected by EV-associated oncogenic signals [55]. EVs also
contribute to the development of a resistant residual disease and to the de-differentiation of cancer
cells towards CSC phenotypes. The EV-based paracrine communication can ensure evolutionary
benefits for both the cancer cells and fibroblasts. Thus, EVs appear to be important factors of the
co-evolution of these cells. EVs modify the therapeutic sensitivity of cells by different mechanisms,
such as (i) by sequestering and releasing drugs from the cells, (ii) conveying drug transporter molecules,
(iii) capturing monoclonal antibodies of target therapy as well as (iv) by affecting post-transcriptional
regulation and receptor-ligand interactions [56].
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Figure 1. Summary of presumptive changes in carci oma-associated fibroblast (CAF) populations,
intratumor l heterogeneity, numbers f cancer cells, and per e tages of survivor ca cer stem cells
(CSC ) during therapy and recurrence. In the cours of chemoth rapy, the majority of cancer cells
(blue) are eliminated (grey). In parallel, the percentage of CSCs (red) may increase in minimal residual
disease (MRD) compared to the gross tumor mass. During recurrence, daughter cells of the resistant
CSCs can repopulate (brown) the tumor. The original CAF population (green) is partially eliminated
(grey) by the therapy. Resistant (yellow) and newly formed CAFs may have dedifferentiated from
normal fibroblasts (NFs) and from bone-marrow-derived mesenchymal stem cells (BM-MSCs) (purple).
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2. Tumor-Stroma Co-Evolution Requires CAF Survival, Recruitment, and Differentiation
2.1. Therapy-Resistant Subpopulations of Carcinoma-Associated Fibroblasts
As we described above, the evolving cancer cells may be crucially dependent on their
specific, reactive microenvironment. This symbiotic relationship between cancer cells and CAFs
may get intensified partially in response to a treatment-related evolutionary pressure [24,42].
For some CAF subpopulations, RT and chemotherapy may act as activators of tumor supportive
functions [48,57–59]. The clinical relevance of the tumor-supporting phenotype of CAFs can be
assessed by using specific resistance markers. Newly identified surface markers such as CD10
and the G protein-coupled receptor 77, may reflect resistance against docetaxel and cisplatin in
double-positive CAFs. Importantly, these CAFs generate a nursing microenvironment (i.e., survival
niche) around aldehyde dehydrogenase 1-positive CSCs under chemotherapeutic pressure in breast
and lung cancer patients [34].
2.2. Treatment-Related Replenishment of CAFs
Besides the resistant subpopulations, which survive anti-cancer therapy, CAFs are also replenished
from other cell types [43]. The CAF-like dedifferentiation of carcinoma cells (via EMT) in experimental
models and human tumors remains controversial. CAF-like phenotypes with EMT features have been
detected both in breast and lung adenocarcinomas [60,61]. Single-cell RNA sequencing also identified
CAFs with potential epithelial tumor origin. This EMT subclass can be distinguished from other
CAFs by its scrapie-responsive protein 1 positivity and by its localization [62]. In contrast, EMT-based
CAF differentiation was questioned in pharynx squamous cell- and colorectal adenocarcinoma
xenografts [63]. In addition, bone-marrow-derived mesenchymal stem or stromal cells (BM-MSCs)
can be recruited by the constantly evolving cancer microenvironment, and may also be important
sources of CAFs. Active migration of BM-MSCs to tumor sites has been demonstrated in several
studies [64,65]. BM-MSCs were detected in the tumor front and were shown to promote the survival of
mammary and lung carcinoma cells upon exposure to paclitaxel or doxorubicin [66]. Furthermore,
BM-MSCs contributed to the increase of CD133, octamer-binding transcription factor 4-positive and
sex determining region Y-box 2-positive CSCs in a prostate cancer co-culture [64]. When cultured
with cancer cells, they can differentiate to the CAF-like phenotype with tumor-supporting effect by
sustained stromal-derived factor 1 expression [67]. Intriguingly, BM-MSCs share important similarities
with CAFs, including (i) the expression of certain cell surface molecules (e.g., CD29, CD44, CD73, CD90,
CD106 and CD117), (ii) the expression cytoskeleton and extracellular matrix proteins (e.g., vimentin,
α-smooth muscle actin and nestin), as well as (iii) retention of pluripotency [68,69]. These data strongly
suggest that BM-MSCs are not only progenitors of CAFs, but CAF-like cells may constitute a distinct
subset of MSCs (i.e., CAF-MSCs).
Several studies described therapy-associated differentiation of fibroblasts to CAF-like cells,
which suggests that fibroblasts in the normal tissue adjacent to the tumor can be important sources
of CAFs. CAF-like differentiation of fibroblasts has been described after using sub-lethal doses
of conventional chemotherapy in breast cancer models [48]. The treatment induced a metabolic
switch in fibroblasts (a so-called catabolic tumor stroma phenotype) with increased secretion of
interleukin-6 (IL-6) in co-cultures and resulted in activating stemness-related signaling (Hedgehog
/GLI) in breast cancer cells [48]. Another study revealed increased transforming growth factor-β
secretion after cisplatin treatment of non-small-cell lung cancer [70]. In turn, transforming growth
factor-β-induced transition of fibroblasts to CAF-like cells with enhanced IL-6 secretion. Furthermore,
CAF-conditioned media induced EMT, acquisition of stemness (i.e., CD133 expression) and cisplatin
resistance in lung cancer cells [70]. MicroRNAs (miRs) as post-transcriptional regulators, may
also take part in fibroblast differentiation to a chemoresistant CAF-like phenotype. For example,
miR-27-transfected fibroblasts convert to CAFs with increased resistance to cisplatin [71]. RT may
also cause biological and transcriptional changes in fibroblasts, which may directly affect stromal
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homeostasis [59]. The genes involved in this process, are related to DNA repair, cell cycle arrest, Wnt
and IGF signaling, as well as to extracellular matrix remodeling [72]. RT can induce α-smooth muscle
actin (fibroblast activation/CAF marker) expression consistent with myofibroblast differentiation in
NIH-3T3 fibroblasts. Interestingly, RT did not affect α-smooth muscle actin, platelet-derived growth
factor receptor-β and neuron-glial antigen 2 expression in NIH-3T3 cells in prostate cancer co-cultures,
but it caused CAF-like differentiation and RT resistance in xenografts [73]. These results show that
RT or chemotherapy induce normal fibroblasts to differentiate into resistant CAFs either directly or
through forced paracrine signaling of the treated cancer cells.
2.3. Differential Cellular Behavior of Resting and Chemotherapy-Treated CAFs
It is also important to note that therapy-pressured CAFs may release cancer (minimal
residual disease/CSCs)-supporting signals in contrast to non-treated CAFs. Elevated proportions
of CD44+/CD24low/− and aldehyde dehydrogenase-positive CSCs (the authors used the term
tumor-initiating cells (TIC)) were induced in CAF cultures when treated with the maximum
tolerated dose of paclitaxel and doxorubicin, compared to low-dose metronomic drug administration.
In addition, maximum tolerated dose-treated patient-derived xenografts (breast cancer cells and
CAFs) demonstrated an increased metastatic capacity compared to low-dose-treated mice. The latter
also showed enhanced treatment response and extended survival [74]. Another study demonstrated
that cisplatin treatment induces IL-11 release in CAFs, leading to chemo-resistance via the IL-11
receptor-α/signal transducer and activator of transcription 3 pathway in lung adenocarcinoma cells [75].
Moreover, CAFs treated with 5-fluorouracil, oxaliplatin and leucovorin promoted self-renewal of
colorectal cancer-initiating cells by IL-17 signaling [58]. The tumorigenic capacity of CAFs was also
increased by either a single ablative dose or a fractionated RT [59,76]. Elevated oncogenic signaling
through fibroblast growth factor and insulin-like growth factor-1 release was also provoked in CAFs
by gamma irradiation as compared to non-treated cells in colorectal and pancreatic cancers [77,78].
These data suggest that (i) the response to therapy of CAFs may be dose-dependent, and (ii) CAF-derived
paracrine signals may play a fundamental role in the protection of residual cancer.
3. Extracellular Vesicle-Mediated Resistance at the Tumor Cell-CAF Interface
As described above, certain CAF subclones may survive different anti-tumor therapies. In parallel,
the eliminated CAFs may be replaced by their progenitors. In addition, therapy-pressured CAFs are
not passive elements of the niche, as they may support tumor growth more efficiently than non-treated
CAFs or normal fibroblasts [26,77]. It is well known that CAF-released soluble factors and extracellular
matrix components affect the sensitivity of cancer cells to therapy, and mediators released by tumors
have an effect on CAF/fibroblast properties.
3.1. Small EV-Induced Resistance in the CAF-Cancer Cell/CSC Axis
EVs can be classified based on their biogenesis. However, as their biogenetic origin often cannot be
confirmed, a temporary nomenclature, based on, e.g., their biophysical properties such as size has been
recently suggested for EVs [79]. Small EVs (sEVs, <200 nm in diameter) have intriguing and significant
roles in the different phases of tumor progression and in the regulation of resistance mechanisms [79–81].
Certain reports described that both CAFs and cancer cells may dramatically increase release of sEVs
with endosomal origin (i.e., exosomes, reviewed in [82]) caused by the effect of irradiation or
chemotherapeutic agents [83–85]. The increased sEV release may be related to an increased DNA
repair and p53 activation, which result in upregulation of tumor suppressor activated pathway-6 [86].
This suggests that the altered sEVs release may serve as an alarm signal in response to the therapeutic
pressure. In general, cancer cell- or CAF-derived sEVs can affect clinically important properties of
recipient cells [87–89]. These include the induced resistance against RT [90] and chemotherapeutic
agents with different mechanisms of action (e.g., alkylating agents [90,91], antimetabolites [83,91,92]
and mitotic inhibitors [87]). In the examples presented in Table 1, sEVs promote (i) signaling cascades
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(e.g., via the Wnt pathway or RNA-activated pattern recognition receptors) and (ii) regulation by miRs
or long non-coding RNAs (lncRNAs). The majority of these studies emphasize the appearance of
CSC phenotype (e.g., CD44, CD133, aldehyde dehydrogenase 1 and leucine-rich repeat-containing G
protein-coupled receptor 5 (Lgr5) expression) and functions (e.g., chemoresistance, sphere formation,
growth, and metastatic spread) as a result of EV-based communication between CAFs and cancer cells
(Table 1). Nevertheless, the mechanism of therapy-induced CSC enrichment remains largely unclear.
The increased percentage of CSC certainly cannot be explained solely by the death of sensitive cells
(Figure 1), but it is rather due to the reprogramming of differentiated cancer cells. One of the main
reprogramming factors is Wnt delivered by fibroblast/CAF-derived sEVs as described in colorectal
carcinoma [92]. Wnt-β-catenin-TCF signaling drives the dedifferentiation of non-stem carcinoma
cells to regain pluripotency and re-express Lgr5 and CD44 [93,94]. CAF-derived sEV miR-92a-3p
caused an increased nuclear β-catenin expression in colorectal carcinoma cells with the appearance
of CSC markers and several processes associated with EMT, such as the E-cadherin to N-cadherin
switch [95]. Importantly, chemotherapy-treated CAF-released sEVs showed differential effects on the
recipient cancer cells as compared to sEVs from untreated but resistant CAFs [83]. This supports the
hypothesis that the cargo of therapy-induced EVs is different from that of the non-therapy-induced
ones [96]. These results suggest that CAF-derived sEVs do not only mediate protective/supportive
signals against the therapeutic stress, but they dynamically control the size of the CSC pool by the
dedifferentiation process.
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Table 1. Tumor cell-CAF EV-based crosstalk and its effect on chemotherapy and radiation therapy (RT).
Tumor Models (Cell Lines) Origin of Extracellular Vesicles(and Used Terms)
Changes (↑↓) of Resistance- and CSC Properties as Well as Expression of
Relevant Molecules and Activation of Pathways in the Recipient Cell
Population.
Ref
Colorectal cancer: (SW620), xenograft CAF-derived sEV(exosome) Resistance to oxaliplatin and 5-FU↑. percentage of CD133
+ CSCs↑, Wnt
activity↑, in cancer cells [91]
Colorectal cancer: (HT29, SW620),
xenograft
Fibroblast (18Co) and CAF-derived sEVs
(exosome)
Resistance to oxaliplatin and 5-FU↑. Wnt activity↑, cancer cell
dedifferentiation to CSC↑, sphere formation ability↑ [92]
Colorectal cancer: (HCT116, SW480),
xenograft CAF-derived sEV (exosome)
Resistance to oxaliplatin↑, percentage of CSC marker positive cells↑, sphere
formation ability↑ [97]
Colorectal cancer: (SW480, SW620, LOVO),
xenograft CAF-derived sEV (exosome)
Resistance to oxaliplatin and 5-FU↑. EMT and CSC markers↑, Wnt activity↑,
mitochondrial apoptosis↓ [95]
Colorectal cancer: (HCT116, SW480),
xenograft CAF-derived sEV (exosome)
Resistance to oxaliplatin and 5-FU↑. colorectal cancer-associated lncRNA↑,
Wnt activity↑ [88]
Pancreatic cancer: (PANC1, AsPC1),
xenograft CAF-derived sEV (exosome)
Gemcitabine resistance↑, Snail↑, miR-146a↑, proliferation↑, survival↑ in
PaC cells [83]
Ovarian cancer: (OVCA432, SKOV),
xenograft CAF-derived sEV (exosome) Resistance to paclitaxel↑, miR-21↑, APAF1↓ in ovarian cancer cells [87]
Ovarian cancer: (A2780, SKOV3),
xenograft CAF-derived sEV (exosome) Resistance to cisplatin↑, CDKN1A↓ in ovarian cancer cells [98]
Breast cancer: (MDA-MB-231), xenograft CAF-derived sEV (exosome)
Resistance to RT and cisplatin↑, IRDS activation↑, RIG-I signaling↑,
CD44+/CD24low CSC subpopulation↑ in basal-like subtypes breast
cancer cells
[90]
Head and neck cancer: (HN4, CAL27),
xenograft CAF-derived sEV (exosome)
Resistance to cisplatin↑, miR-196a↑, CDKN1B↓, ING5↓ proliferation↑,
in recipient cancer cells [99]
Breast cancer cells: (MDAMB23) Tumor-derived sEV (exosome) Paclitaxel treated tumor-derived sEVs promotes survival of fibroblasts [89]
Prostate cancer: (PC3, LnCaP) Tumor-derived mEV, fibroblast-derivedmEV (microvesicle)
Tumor-derived mEV treated fibroblasts: chemosensitivity against
actinomycin D↓, ERK1/2 phosphorylation↑, MMP9↑, migration↑.
Fibroblast-derived mEV treated PC3 cells: migration↑, invasion ↑
[100]
Lung cancer: (LL-2, A549, HTB177),
xenograft Tumor-derived mEV (microvesicle)
Release of IL-1, -6, -8, -11↑, VEGF↑, LIF↑, OSM↑ and MMP9↑ in fibroblasts.
Conditioned media of tumor-mEV treated fibroblasts: adhesion between
LL-2 and HUVECs cells↑, metastatic potential of lung cancer cells↑
[101]
APAF1: apoptosis protease-activating factor-1; CDKN1B: cyclin dependent kinase inhibitor 1B; HUVECs: human umbilical vein endothelial cells; ERK1/2: extracellular signal-regulated
kinase 1/2; ING5: inhibitor of growth 5; IRDS: interferon-related DNA damage resistance signature; LIF: leukemia inhibitory factor; MMP: matrix metalloproteinase; OSM: oncostatin M;
RIG-I: retinoic acid-inducible gene-I-like receptor.
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3.2. Medium-Sized EV Communication in Resistance Development of Tumor Cells and CAFs
Medium-sized EVs (mEVs, earlier often designated as microvesicles) are directly produced
by plasma membrane shedding and are characterized by heterogeneous size (~100 nm to 1 µm in
diameter) [102]. mEVs are potent intercellular regulators with selectively loaded cargo, some of which
appear to be associated with an unfavorable clinical outcome. Although the oncogenic effects of
mEVs are less studied than those of sEVs, mEVs may have a bigger impact on the same processes as
compared to sEVs. For example, CAF-derived mEVs show a strong influence on the proliferation
of prostate cancer cells as compared to sEVs from the same CAF culture [103]. Stress factors, such
as non-apoptotic doses of hypoxia or irradiation increase the secretion of tumor-derived mEVs in
lung cancer cells. These fibroblasts showed increased secretion of soluble pro-angiopoietic and
extracellular matrix-degrading factors (see Table 1 below for details). Functionally, by the activation
of the mEV-fibroblast axis, tumor cells indirectly enhanced the angiogenic crosstalk in the tumor
microenvironment [101]. Tumor-derived mEVs from prostate cancer cells decreased chemosensitivity in
activated fibroblasts through phosphorylation of extracellular signal-regulated kinase 1/2. In addition,
tumor-derived mEV treatment caused an increased mEV shedding from fibroblasts and this affected
migration and invasion of highly metastatic PC3 cancer cells in vitro [100] (Table 1). Extracellular
signal-regulated kinase 1/2 signaling was also involved in the metabolic switch of CAFs. This metabolic
reprogramming provides energy-rich metabolites to adjacent cancer cells (i.e., reverse Warburg effect)
and promotes survival of cancer cells in a nutrient-deprived environment. Oral squamous cell
carcinoma-derived mEVs induce a metabolic switch from mitochondrial oxidation to glycolysis via
transfer of phosphorylated extracellular signal-regulated kinase 1/2 and consequential degradation
of caveolin 1 in normal fibroblasts. Tumor-derived mEV treatment increases lactate production in
fibroblasts/CAFs, which consequently supports cancer progression in vitro and in vivo [104]. Caveolin
1-reduced, glycolytic CAFs protect estrogen receptor-positive MCF7 breast cancer cells against
tamoxifen-induced apoptosis. Dasatinib, a tyrosine kinase inhibitor prevents the loss of caveolin 1 in
CAFs and restores tamoxifen-sensitivity in MCF7 cells [105]. Summarizing these results, mEVs are
multifunctional effectors in cancer cell-fibroblast/CAF interactions during the reaction to therapy and
affect many cancer-related processes, such as metastatic potential, altered metabolism, and sensitivity
of recipient cells.
3.3. Apoptotic Cell-Derived EVs in the Development of Resistance, Relapse, CSC Phenotype and Metastasis
Several studies denote that the regenerative responses to cancer cell apoptosis paradoxically
generate supporting signals and promote post-therapeutic relapse of residual tumors [106,107].
Apoptotic cell-derived EVs (apoEVs) are released because of the activation of the apoptosis effector
machinery. ApoEVs carry a variety of bioactive molecules similarly to other vesicles. Furthermore,
they contain caspase-modified autoantigens, nuclear remnants containing condensed chromatin,
cellular organelles such as mitochondria and endoplasmic reticulum [108,109]. ApoEVs show a
continuum in their size distribution (50–5000 nm in diameter) including the large apoptotic bodies
(>1000 nm in diameter) [83]. Horizontal transfer of potentially oncogenic, genomic DNA through
apoEVs may lead to the sustained transformation of recipient cells [108]. Tumor-derived apoEVs
stimulate proliferation (termed compensatory proliferation or apoptosis-induced proliferation [108])
of surviving cancer cells in neighboring compartments [23]. The question can be raised whether these
signals between apoptotic and surviving cancer cells lead to dedifferentiation to CSCs. An answer
to this question is suggested by the observation that apoEVs induce proneural-to-mesenchymal
transition (EMT-like phenotypic change) in glioblastoma cells with the appearance of CSC properties,
such as expression of CD44 and aldehyde dehydrogenase 1A3, as well as resistance to therapy [23].
Emerging evidence suggests that apoptotic signals from dying cancer cells may promote a more
supporting microenvironment called “onco-regenerative niche” [109]. For instance, mouse embryonic
fibroblasts, deficient in p53 can reutilize H-rasV12, c-myc, and hygromycin resistance genes carried
by apoEVs of cancer gene-transfected rat fibroblasts after their irradiation or nutrient-depletion
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to provide a selection advantage to the recipient cells [110]. Although, apoEV-based oncogenic
gene transfer has been described between fibrosarcoma cells and p53-inactivated fibroblasts [111],
only little is known about the significance of apoEV-based cancer cell-fibroblast/CAF interactions
in therapy-induced stress reaction and post-therapeutic relapse. Starvation-induced, dying gastric
carcinoma cell-derived apoEVs can promote co-invasion of the surviving cancer cells as small clusters
with CAFs (i.e., CAF-led type invasion) [112]. To sum up these results, apoEVs may play a role in
important processes of therapeutic and post-therapeutic tumor evolution, such as compensatory
proliferation, horizontal oncogene transfer, and regulation of invasion.
4. Conclusions
Anti-cancer therapies may act as double-edged swords. Besides their oncoreductive effects,
they may also promote tumor evolution and progression though increasing the selection pressure
on the surviving cells based on intratumoral heterogeneity. In cancer cells, treatment-related stress
may be buffered by cells of the tumor microenvironment, especially CAFs. Accumulating data have
shown that a therapy-induced, EV-based communication between fibroblasts/CAFs and the adjacent
tumor mass may be critical in the cancer-stroma co-evolution and enrichment in the CSC populations.
This leads to minimal residual disease, metastatic spread and tumor recurrence (Figure 2). The results
overviewed from a variety of model systems, suggest that these treatment-induced interactions may
occasionally endow tumors with a behavior, which is less favorable than what they had before the
treatment. EVs can be crucial messengers here, their production is enhanced, and their molecular
composition is modified upon treatment and tumor progression. Thus, EVs contribute to the
intimate interplay between the cancer and the adjacent stroma. Therefore, it appears plausible
that treatment-resistant surviving cancer cells may release a distinct EV profile. Furthermore,
treatment-induced apoEVs may also carry nursing signals both towards cancer cells and stromal
cells. All these features of EVs warrant high plasticity for the complex tumor tissue through
activating diverse and simultaneous molecular pathways. Cancer cell and fibroblast subtypes, their
therapy and time-dependent responses add further complexity to the EV-based interactions in the
tumor-stroma co-evolution. Combined analysis of genetic and epigenetic features including tumor
and EV heterogeneity may support the identification of novel therapeutic targets for more efficient
cancers treatments.
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